Additionally, BTK inhibitors, including rilzabrutinib and orelabrutinib, have shown potential in clinical trials, offering increased platelet stability and favorable safety profiles in ITP cases. This evidence concerns the gene BTK and autoimmune thrombocytopenic purpura.